COA ↓

Product

COA Doc

SYN-2610

99.4% Purity SYN-2610 Research Grade HPLC Verified

BPC-157 + TB-500 Stack

Dual-Peptide Recovery Complex · Research Grade

Select Strength — 10mg

$120.00

C₆₂H₉₈N₁₆O₂₂ / C₂₁₂H₃₅₀N₅₆O₇₈S MW: 1419.56 / 4963.44 g/mol CAS: 137525-51-0 / 77591-33-4

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.4% / 99.0%

HPLC Purity

Lot Number SYN-2610-STK

Test Date March 2025

Labeled 5 mg each

Actual 5.02 / 5.01 mg

99.3% / 99.1%

HPLC Purity

Lot Number SYN-2609-STK

Test Date January 2025

Labeled 5 mg each

Actual 5.03 / 5.02 mg

Research Data

KEY FINDINGS

🔬

Complementary Mechanisms

FAK-paxillin (local) + actin sequestration (systemic)

🩹

2.6×

BPC-157 Migration Rate

Local tissue repair via FAK-paxillin pathway activation

🔄

2.8×

TB-500 Migration Rate

Systemic healing via actin sequestration and stem cell recruitment

❄️

24mo

Shelf Life at −20°C

Both vials lyophilised under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 Dual Pathway

Complementary Mechanisms of Action

BPC-157 and TB-500 target tissue repair through entirely independent molecular pathways, making them mechanistically additive rather than redundant when combined in research protocols.

BPC-157 — FAK-paxillin Site-specific

BPC-157 — VEGF/eNOS Local angiogenesis

TB-500 — G-actin sequest. Systemic motility

TB-500 — SDF-1/CXCR4 Stem cell recruitment

🔬 No published research has identified pathway overlap or competitive inhibition between BPC-157 and TB-500 mechanisms of action.

PMID 30107218 — J. Physiol. Pharmacol.

🩹 BPC-157 Component

FAK-Paxillin & VEGF Activity

BPC-157 activates the FAK-paxillin signalling cascade in tendon fibroblasts and upregulates VEGF in endothelial cells — driving localised tissue repair and angiogenesis at the site of injury.

🔬 BPC-157 accelerates fibroblast migration 2.6× and upregulates VEGF by 92% in in vitro models of tissue injury.

PMID 24481223 — Eur. J. Pharmacol.

🔄 TB-500 Component

Actin Sequestration & Stem Cell Mobilisation

TB-500 sequesters G-actin monomers to enable rapid cell migration and upregulates SDF-1/CXCR4 to mobilise circulating stem cells — providing systemic repair support independent of BPC-157's localised activity.

🔬 TB-500 mobilises stem cells 3.1× more effectively than untreated controls and increases directional cell migration 2.8× via G-actin sequestration.

PMID 26297961 — Ann. N.Y. Acad. Sci.

2 pathways

Dual Complementary Repair Mechanisms

BPC-157 targets localised tissue repair via the FAK-paxillin pathway and VEGF upregulation, while TB-500 provides systemic healing through G-actin sequestration and stem cell mobilisation — together covering both site-specific and body-wide recovery simultaneously.

Mechanism Coverage — BPC-157 vs TB-500 vs Stack

Stack (both) 100%

BPC-157 only 62%

TB-500 only 58%

Source: Published in vitro studies, combined pathway analysis

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2610-STK

Specification	Value
CAS Number	137525-51-0 / 77591-33-4
Molecular Formula	C₆₂H₉₈N₁₆O₂₂ / C₂₁₂H₃₅₀N₅₆O₇₈S
Molecular Weight	1419.56 / 4963.44 g/mol
Purity (HPLC)	99.4%
Appearance	White lyophilised powder (dual-vial kit)
Solubility	Both: Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term (store vials separately)
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

4 pathways

Simultaneous Repair Mechanisms vs. Single-Peptide Use

Stack (BPC + TB) 4 pathways

BPC-157 alone 2 pathways

TB-500 alone 2 pathways

Growth Factor 1 pathway

Comparative Activity Profile

Stack BPC-157 TB-500

Observed Adverse Indicators

Cytotoxicity (either compound)

None

Genotoxic effects

None

Combined angiogenic promotion

Minimal

Synergistic off-target effects

None observed

⚠️ Theoretical Concern

Additive Angiogenic Activity

Both compounds promote angiogenesis via separate mechanisms (VEGF/FAK for BPC-157; eNOS/SDF-1 for TB-500). Researchers studying angiogenesis-sensitive models should account for this combined activity.

No cytotoxicity or genotoxicity for either compound in published in vitro studies
Combinatorial angiogenic effect is expected and consistent with the stack's research application
Store vials separately after reconstitution to maintain individual compound stability